A new ovarian cancer study suggests fructose may play an unexpected role after chemotherapy, helping surviving tumor cells create conditions that make it easier for cancer to spread. The finding is still preclinical, but it raises provocative questions about metabolism, treatment — and diet.
August 22, 2026- For years, the relationship between sugar and cancer has been reduced to an irresistible but frustratingly incomplete phrase: sugar feeds cancer. There is some biology behind the idea. Many cancer cells consume glucose at unusually high rates, and the altered metabolism of tumors has been studied for decades. But a new study of ovarian cancer suggests that focusing only on how much sugar a tumor consumes may miss a more interesting part of the story.
The sugar at the center of this research is fructose, and its apparent role is not simply to provide calories for a growing tumor. Researchers found evidence that fructose can alter the way ovarian cancer cells behave, making it easier for them to detach from one another and disseminate. More unexpectedly, the fructose appeared after chemotherapy, produced by cancer cells that had survived treatment. And when researchers increased fructose exposure in animals independently of chemotherapy, cancer spread increased as well.
The study, “The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming,” was published July 30 in Nature Aging by researchers led by Katherine Aird and colleagues at The Wistar Institute in Philadelphia. The work focused on high-grade serous ovarian cancer, an aggressive form of the disease in which recurrence and spread remain major clinical problems.
What the researchers uncovered complicates not only the familiar story about sugar and cancer, but also the way we think about what happens to a tumor after chemotherapy.
The cancer cells chemotherapy leaves behind
Chemotherapy is usually described in terms of the cells it kills. But treatment also leaves survivors, and those survivors are becoming increasingly interesting to cancer researchers: some cancer cells exposed to chemotherapy enter a state known as cellular senescence. They stop dividing, which might sound like an acceptable outcome: a cancer cell that no longer multiplies would seem to have been neutralized. Yet senescent cells are not dead. They remain biologically active, continue metabolizing nutrients, and release a collection of substances into the space around them.
That distinction was central to the Wistar study. The researchers collected the material released by ovarian cancer cells that had survived chemotherapy and exposed other tumor cells to it. Those neighboring cells became more capable of spreading. In animal models, the secreted material alone was enough to increase dissemination, suggesting that the surviving cells did not need to travel anywhere themselves to influence the course of the disease. They could alter the behavior of other cancer cells from a distance.
The next question was obvious: What were those surviving cells releasing?
Among the molecules the researchers identified was an unexpected one — fructose.
“We discovered that cells surviving chemotherapy release fructose,” senior author Katherine Aird told Medical News Today. The finding turned a familiar dietary sugar into something more biologically intriguing: in this setting, fructose appeared to function as a signal capable of changing the behavior of neighboring tumor cells.
Fructose was not simply feeding the tumor
The distinction matters. The study was not merely showing that cancer cells can burn fructose for energy. Instead, the researchers traced a metabolic change that affected how firmly the cells remained attached to one another. And that is where cholesterol entered the picture. Cholesterol is usually discussed as something circulating in the bloodstream, measured in a lipid panel and associated with cardiovascular risk. But cholesterol is also an essential structural component of cell membranes. In the ovarian cancer cells studied here, it helped maintain the physical connections that kept cells clustered together.
When neighboring tumor cells processed the fructose released by chemotherapy-surviving cells, their cholesterol production fell. As cholesterol declined, the bonds holding those cells together weakened. Cells were more able to detach from the tumor mass — an important step in metastasis. The Wistar researchers have described cholesterol in this setting as a kind of biological “glue.” Less of it meant that cancer cells could escape more easily.
That makes the finding considerably more interesting than the slogan that cancer “likes sugar.” Here, fructose appears to be changing the physical behavior of the tumor through metabolism. In simplified terms, the sequence looks something like this: chemotherapy leaves behind metabolically active cancer cells; those cells create a fructose-rich environment; neighboring cancer cells process the fructose; cholesterol production falls; cellular adhesion weakens; and cancer cells become better equipped to break away and spread.
It is a chain of events that offers one possible explanation for a longstanding clinical problem: a tumor can initially respond to chemotherapy and yet later recur or metastasize.
Then the researchers brought diet into the experiment
Once fructose emerged as a key player in the laboratory, the research team asked a more provocative question. What would happen if fructose availability increased even without chemotherapy? In animal models, high fructose exposure increased ovarian cancer dissemination on its own. The result does not establish what happens in women eating different diets during cancer treatment, but it suggests that the source of fructose may not have to be the chemotherapy-surviving tumor cell itself. If enough fructose is available from outside the tumor, cancer cells may be able to exploit it.
This is where the study inevitably moves from laboratory biology into a much larger conversation about food.
Fructose occurs naturally in fruit and honey. It is also part of sucrose — ordinary table sugar — and is abundant in many sugar-sweetened drinks and ultraprocessed foods, particularly those made with high-fructose corn syrup. These sources should not be treated as nutritionally identical. A piece of whole fruit comes packaged with fiber, water and micronutrients and delivers fructose very differently from a large sweetened beverage.
Nor did the study demonstrate that eating fruit causes ovarian cancer to spread. It did not compare cancer outcomes among women eating oranges, drinking soda or avoiding sugar. That would be a very different study, and those human data do not yet exist. But the dietary experiment makes it equally difficult to dismiss fructose availability as irrelevant. The researchers deliberately increased fructose exposure and observed more cancer dissemination in animals. That is not a clinical recommendation, but it is a biological signal worth investigating.
Fructose does not necessarily have to come from food
There is another wrinkle that makes the story more complex. Fructose is something we eat, but it can also be produced inside the body: human cells are capable of converting glucose into fructose through what is known as the polyol pathway. Glucose is first converted into sorbitol — the same chemical compound also used commercially as a sugar alcohol sweetener — and sorbitol can then be converted into fructose. The sorbitol produced inside the body is not there because someone ate a sugar-free candy; it is part of normal cellular chemistry that can become more active under certain metabolic conditions.
The new study establishes fructose production by chemotherapy-surviving cells, although questions remain about exactly how those cells generate and regulate it. That distinction will matter as researchers try to understand whether tumor-produced fructose, dietary fructose and the body's own fructose production contribute differently to cancer progression.
In other words, reducing this story to “avoid fructose” would miss much of what makes the discovery important. The tumor itself appears capable of reshaping its nutrient environment.
An unexpected cholesterol question
The cholesterol finding creates another potentially important — and delicate — area for research.
Statins lower cholesterol synthesis, which is precisely why they are widely prescribed to reduce cardiovascular risk. In the Wistar experiments, however, statins also reduced the cellular “glue” associated with cholesterol and promoted cell escape. The researchers are now investigating whether cholesterol-lowering drugs could interact with chemotherapy in ways that matter for ovarian cancer.
That finding is nowhere near enough to conclude that statins cause ovarian cancer to spread, and the investigators explicitly caution patients not to stop taking prescribed medication. What it does provide is a reminder that cholesterol biology inside a cancer cell is not necessarily the same question as cholesterol circulating in the blood. A drug that is beneficial in one physiological context can have effects worth studying in another.
The issue may be especially relevant because ovarian cancer is most common in older women, a population in which statin use is also common. For now, however, this remains a research question, not a reason to change clinical practice.
None of this means chemotherapy should be abandoned
There is another conclusion that the researchers are particularly careful to avoid. If chemotherapy can leave behind senescent cells that promote metastasis, does that mean chemotherapy itself is making cancer worse? No.
Chemotherapy remains one of the most important treatments available for ovarian cancer and can produce substantial responses. The lesson from the study is not that physicians should stop using it, but that eliminating actively dividing tumor cells may not be the end of the biological story. What happens to the cells that survive treatment — and what those cells subsequently release — could offer new targets for therapy.
Aird's team is already exploring ways of reducing fructose production in surviving cells and has identified an FDA-approved diabetes drug that may potentially interfere with the process. That work, too, remains preclinical.
The broader idea is compelling. Rather than viewing chemotherapy simply as a weapon that kills or fails to kill individual cancer cells, researchers are beginning to look at how treatment changes the ecosystem of a tumor. A surviving cell may no longer be dividing, yet it can continue communicating with its neighbors, altering their metabolism and potentially changing their ability to move.
The diet question is no longer so easy to dismiss
Nutrition during cancer treatment has traditionally been approached largely through the practical problems patients face: maintaining adequate calories and protein, preventing weight loss, managing nausea and preserving strength. Those goals are essential and are not challenged by this study. But cancer metabolism research is making another question increasingly difficult to avoid: Could the nutrients available to cancer cells affect not only how quickly they grow, but what they are capable of doing? The fructose study does not answer that question for patients. It does not establish a therapeutic diet for ovarian cancer, identify a safe threshold for fructose intake or demonstrate that removing a particular food changes survival. The authors themselves emphasize that their findings have not yet been confirmed in humans.
Still, the results challenge the idea that diet and conventional cancer treatment necessarily occupy separate worlds. If chemotherapy can reprogram surviving cancer cells to produce a nutrient that facilitates metastasis, and if increasing the same nutrient from outside the tumor can reproduce part of that effect in animals, then the interaction between treatment and nutrition deserves closer scrutiny.
This is particularly relevant in a food environment where concentrated fructose can be consumed easily and rapidly through soft drinks, sweetened beverages and a wide range of ultraprocessed products. That does not make an orange equivalent to a soda, and it does not turn dietary restriction into cancer therapy. It does make the metabolic context in which treatment occurs a legitimate scientific question.
The most interesting conclusion from this research, then, is not that “sugar feeds cancer.” We already knew that many tumors have an enormous appetite for glucose, and the reality has always been more complicated than the slogan suggests. The surprise is that fructose may be doing something different. It may be helping cancer cells become less attached, more mobile and better able to spread. If that mechanism holds up in human studies, it could change the conversation about what happens after chemotherapy — and perhaps eventually about the role nutrition plays alongside cancer treatment.
For now, that remains a possibility rather than a prescription. But it is a possibility worth taking seriously.
Sources
Cole AR, Buj R, Uboveja A, et al. “The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming.” Nature Aging. Published July 30, 2026.
The Wistar Institute. “Wistar Scientists Identify Fructose as a Surprise Driver of Cancer Spread.” July 30, 2026.
Add comment
Comments